128,006 Shares in Maze Therapeutics, Inc. $MAZE Acquired by Walleye Capital LLC

Key Points

• Walleye Capital acquired 128,006 shares of Maze Therapeutics during the second quarter, a position valued at approximately $3.82 million and representing 0.23% of the company.
• MAZE shares opened at $27.18 and are down 1.8%, while the company reported a quarterly loss of $0.76 per share, in line with estimates. Analysts maintain a consensus “Buy” rating with an average price target of $66, despite the company remaining unprofitable.
• Insiders sold 140,674 shares worth about $3.9 million over the past 90 days, including sales by the CEO and chief marketing officer under pre-arranged Rule 10b5-1 plans.

Walleye Capital LLC purchased a new position in Maze Therapeutics, Inc. (NASDAQ:MAZE - Free Report) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 128,006 shares of the company's stock, valued at approximately $3,820,000. Walleye Capital LLC owned 0.23% of Maze Therapeutics at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Royal Bank of Canada increased its position in Maze Therapeutics by 128.3% in the fourth quarter. Royal Bank of Canada now owns 646 shares of the company's stock worth $27,000 after buying an additional 363 shares in the last quarter. Ameritas Investment Partners Inc. lifted its holdings in Maze Therapeutics by 82.6% during the third quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company's stock valued at $42,000 after purchasing an additional 738 shares in the last quarter. California State Teachers Retirement System lifted its holdings in Maze Therapeutics by 138.0% during the fourth quarter. California State Teachers Retirement System now owns 1,321 shares of the company's stock valued at $55,000 after purchasing an additional 766 shares in the last quarter. Police & Firemen s Retirement System of New Jersey increased its stake in shares of Maze Therapeutics by 18.5% in the fourth quarter. Police & Firemen s Retirement System of New Jersey now owns 5,961 shares of the company's stock worth $247,000 after purchasing an additional 931 shares in the last quarter. Finally, GF Fund Management CO. LTD. bought a new stake in shares of Maze Therapeutics during the 4th quarter valued at $39,000.

Maze Therapeutics Trading Down 1.8%

Shares of MAZE stock opened at $27.18 on Friday. The company has a current ratio of 18.31, a quick ratio of 17.88 and a debt-to-equity ratio of 0.09. The stock has a market capitalization of $1.51 billion, a price-to-earnings ratio of -10.79 and a beta of 2.21. Maze Therapeutics, Inc. has a 12-month low of $12.81 and a 12-month high of $53.65. The stock's 50-day moving average price is $27.79 and its 200-day moving average price is $33.03.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.76) earnings per share for the quarter, meeting the consensus estimate of ($0.76). Equities research analysts predict that Maze Therapeutics, Inc. will post -2.74 EPS for the current fiscal year.

Insider Buying and Selling at Maze Therapeutics

In other news, CMO Harold Bernstein sold 16,142 shares of the company's stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $27.61, for a total transaction of $445,680.62. Following the sale, the chief marketing officer directly owned 16,142 shares in the company, valued at approximately $445,680.62. This represents a 50.00% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Jason V. Coloma sold 34,501 shares of the firm's stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $29.98, for a total value of $1,034,339.98. Following the completion of the sale, the chief executive officer directly owned 23,337 shares of the company's stock, valued at $699,643.26. The trade was a 59.65% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 140,674 shares of company stock worth $3,904,707 over the last 90 days. 5.30% of the stock is owned by insiders.

Analyst Ratings Changes

Several equities analysts have recently commented on MAZE shares. Wall Street Zen downgraded Maze Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday. BTIG Research reissued a "buy" rating and set a $46.00 target price on shares of Maze Therapeutics in a research note on Wednesday. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Maze Therapeutics in a report on Wednesday, June 24th. Two investment analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $66.00.

Maze Therapeutics News Summary

Here are the key news stories impacting Maze Therapeutics this week:

• Positive Sentiment: BTIG issued a Buy rating. The endorsement adds to the constructive analyst view of Maze’s pipeline and could support investor confidence. Maze Therapeutics Earns Buy Rating from BTIG Research
• Positive Sentiment: Maze strengthened its board with two experienced executives. Paula Johnson, M.D., M.P.H., and Sophie Kornowski, Pharm.D., M.B.A., bring extensive clinical, pharmaceutical, partnering, and commercialization expertise. Management also highlighted additional MZE829 data in late 2026 or early 2027, initial MZE782 data in 2027, and additional trial starts next year. Maze Therapeutics Announces Appointments to Its Board of Directors
• Positive Sentiment: HC Wainwright raised all of its reported EPS forecasts. Estimates improved for third-quarter 2026, fourth-quarter 2026, and fiscal years 2026 through 2030. For example, FY2026 EPS was revised to a loss of $2.81 from $2.96, while FY2030 was revised to a loss of $0.72 from $0.74, indicating expectations for a somewhat faster reduction in losses over time.
• Neutral Sentiment: Maze reported second-quarter 2026 financial results and recent business highlights. The available report headline does not provide the detailed financial figures, so the earnings release’s impact cannot be fully assessed from the supplied information. Maze Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
• Negative Sentiment: Maze remains unprofitable. HC Wainwright’s revised forecasts still call for substantial losses through 2030, and its FY2026 estimate of a $2.81 loss is slightly worse than the $2.73 consensus forecast.
• Negative Sentiment: Reported insider activity is a concern. Company insiders have recorded sales but no purchases during the past six months, potentially weighing on sentiment.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc NASDAQ: MAZE is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze's approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source